| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Veru Inc. | Sabizabulin (VERU-111) - (VERACITY) | Castration Resistant Prostate Cancer | Phase 3 | Trial Completed | Oral | Oncology |
| Veru Inc. | Sabizabulin (VERU-111) - (VERACITY) | Castration Resistant Prostate Cancer | Phase 3 | Trial Completed | Oral | Oncology |
| Veru Inc. | Enobosarm - (ARTEST) | ER+/HER2- breast cancer | Phase 3 | Looking for Funding | oral | Oncology |
| Veru Inc. | Sabizabulin (VERU-111) | COVID-19 / Severe Acute Respiratory Syndrome, SARS-CoV-2, Influenza A and B, Respiratory Syncytial Virus (RSV) and other viruses | Phase 3 | Trial Discontinued | Oral | COVID-19 |
| Veru Inc. | Sabizabulin (VERU-111) - (VERACITY) | Castration Resistant Prostate Cancer | Phase 3 | Trial Completed | Oral | Oncology |
| Veru Inc. | Enobosarm with semaglutide (Wegovy) - (PLATEAU) | Obesity | Phase 2b | Trial Planned | Oral | Endocrinology |
| Veru Inc. | Sabizabulin (VERU-111) | Triple Negative Breast Cancer | Phase 2b | Trial Discontinued | Oral | Oncology |
| Veru Inc. | VERU-100 | Prostate cancer | Phase 2 | Trial Discontinued | Subcutaneous | Oncology |